BiotechTube
ProteoNova

ProteoNova

San Diego, United States· Est.
proteonova.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

ProteoNova is a private, pre-revenue biotechnology company with a novel platform technology called AcPET, which accelerates protein synthesis for drug discovery and development. Founded in 2002, the company is led by a small team of founders and advisors with backgrounds in biotech, medicine, and business. Its core value proposition is drastically reducing the multi-billion dollar costs and decade-plus timelines of traditional protein therapeutic development, potentially enabling biopharma partners to pursue more candidates simultaneously.

Oncology

Technology Platform

Accelerated Protein Evolution Technology (AcPET) system for rapid, cost-effective protein synthesis for therapeutics and diagnostics.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The platform targets the multi-billion dollar inefficiency in early-stage drug discovery, offering potential order-of-magnitude reductions in cost and time.
This could enable biopharma companies to dramatically expand and de-risk their pipelines.
The technology's applicability to both therapeutics and diagnostics broadens its potential market and partnership opportunities.

Risk Factors

The company faces high technology validation risk, as its extraordinary claims are not yet publicly substantiated.
As a small, private, pre-revenue company, it carries significant funding and execution risk.
It also operates in a highly competitive landscape against well-capitalized firms using AI and advanced automation for protein engineering.

Competitive Landscape

ProteoNova competes in the rapidly evolving field of protein design and engineering, which includes large tool companies (e.g., Thermo Fisher, Danaher), specialized biotechs (e.g., AbCellera, Generate Biomedicines), and numerous AI-driven drug discovery platforms (e.g., Recursion, Insilico Medicine). Its success depends on proving superior speed, cost, or versatility compared to these established and emerging technologies.

More companies in Proteomics & Protein Engineering →More companies in United States →